Cost-effectiveness of evidence-based pharmacotherapy or cognitive behavior therapy compared with community referral for major depression in predominantly low-income minority women

Arch Gen Psychiatry. 2005 Aug;62(8):868-75. doi: 10.1001/archpsyc.62.8.868.

Abstract

Background: Few clinical trials have evaluated interventions for major depressive disorder in samples of low-income minority women, and little is known about the cost-effectiveness of depression interventions for this population.

Objective: To evaluate the cost-effectiveness of pharmacotherapy or cognitive behavior therapy (CBT) compared with community referral for major depression in low-income minority women.

Design, setting, and participants: A randomized clinical trial was conducted in 267 women with current major depression.

Interventions: Participants were randomly assigned to pharmacotherapy (paroxetine hydrochloride or bupropion hydrochloride) (n = 88), CBT (n = 90), or community referral (n = 89).

Main outcome measures: The main outcomes were intervention and health care costs, depression-free days, and quality-adjusted life years based on Hamilton Depression Rating Scale scores and Medical Outcomes Study 36-Item Short-Form Health Survey summary scores for 12 months. Cost-effectiveness ratios were estimated to compare incremental patient outcomes with incremental costs for pharmacotherapy relative to community referral and for CBT relative to community referral.

Results: Compared with the community referral group, the pharmacotherapy group had significantly lower adjusted mean Hamilton Depression Rating Scale scores from the 3rd month through the 10th month (P = .04 to P<.001) of the study, and the CBT group had significantly lower adjusted mean scores from the 5th month through the 10th month (P = .03 to P = .049). There were significantly more depression-free days in the pharmacotherapy group (mean, 39.7; 95% confidence interval, 12.9-66.5) and the CBT group (mean, 25.80; 95% confidence interval, 0.04-51.50) than in the community referral group. The cost per additional depression-free day was USD 24.65 for pharmacotherapy and USD 27.04 for CBT compared with community referral.

Conclusions: Effective treatment for depression in low-income minority women reduces depressive symptoms but increases costs compared with community referral. The pharmacotherapy and CBT interventions were cost-effective relative to community referral for the health care system.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Antidepressive Agents, Second-Generation / economics
  • Antidepressive Agents, Second-Generation / therapeutic use*
  • Bupropion / economics
  • Bupropion / therapeutic use*
  • Cognitive Behavioral Therapy / economics*
  • Cognitive Behavioral Therapy / methods
  • Community Mental Health Services / economics
  • Cost-Benefit Analysis
  • Depressive Disorder, Major / drug therapy*
  • Depressive Disorder, Major / economics
  • Drug Costs / statistics & numerical data
  • Female
  • Health Care Costs / statistics & numerical data
  • Health Status
  • Humans
  • Minority Groups / statistics & numerical data*
  • Paroxetine / economics
  • Paroxetine / therapeutic use*
  • Poverty / economics*
  • Quality of Life
  • Referral and Consultation / economics
  • Selective Serotonin Reuptake Inhibitors / economics
  • Selective Serotonin Reuptake Inhibitors / therapeutic use*
  • Sex Factors
  • Treatment Outcome

Substances

  • Antidepressive Agents, Second-Generation
  • Serotonin Uptake Inhibitors
  • Bupropion
  • Paroxetine